
Zwingenberg (Germany), July 21st, 2021

Novel Genome Editing Tool: Filing of International Patent Application

- **Positive data evaluation**
- **Management sees strong IP position**
- **Seeking international patent protection (PCT)**

Positive data evaluation from recently conducted experiments has increased confidence of BRAIN Biotech AG's management in the valuable IP position of its Non-Cas9 genome editing nuclease, the BRAIN Engineered CAS (BEC). In order to secure a broad intellectual property position on a global scale BRAIN has now advanced in the international patent filing process under the Patent Cooperation Treaty (PCT) formalities. BRAIN is striving for an extended patent family around its BEC genome editing tool to further progress on the IP position already within the course of this year.

BRAIN's novel CRISPR associated first choice nuclease, BEC, has been validated internally as well as with partners and has already been applied in selected bacteria, fungi and yeast. Auspicious genome editing in plant cells has been achieved and is in the process to be validated. Optimization and further development for additional application fields such as mammalian cell lines have been initiated with high priority and a first IP application to protect BRAIN's nuclease sequences has been submitted to the European Patent Office. Additionally IP on several additional sequences has been filed and the nucleases are available for further exploration also with partners.

Dr. Michael Krohn, Head R&D at BRAIN Biotech AG states: "The data evaluation from our recent experiments has been very encouraging. BRAIN's genome editing nuclease is working already well within selected microorganisms and is significantly differentiated from already known Cas nucleases. Above all, experiments in plants and mammalian cell lines are ongoing."

Lukas Linnig, CFO of BRAIN Biotech AG emphasizes: "We are very pleased with the results from our R&D team and have now an even increased confidence in our intellectual property situation. This has been an important milestone to us and has triggered us to accelerate the patent internationalization strategy in major markets. Our Cas nuclease discovery program holds significant economic potential for BRAIN, hence it is important to secure a broad and international IP protection as early as possible."

On May 6th, 2021, BRAIN had announced the development of a novel CRISPR Cas tool using metagenomics sequencing and protein engineering to isolate a Non-Cas9 genome editing nuclease, the BRAIN Engineered Cas (BEC).

About BRAIN

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Contact Investor Relations

Michael Schneiders
Head of Investor Relations & Sustainability
Phone: +49 6251 9331-86
Email: mis@brain-biotech.com

Media Contact

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)